Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Drug Makers Say Japan's PMDA Drug Review Performance Improving

This article was originally published in PharmAsia News

Executive Summary

Japan's drug review body, the Pharmaceutical and Medical Device Agency, has significantly improved performance of the drug review process, demonstrated by shortened review times and higher satisfaction ratings, said the Office of Pharmaceutical Industry Research, a policy think tank under the industry trade association Japan Pharmaceutical Manufacturers Association

You may also be interested in...



Japan's Clinical Trial Costs Average ¥2 Million; Number Of Trials On The Rise

TOKYO - The number of clinical trials being performed in Japan is trending upward every year, but trial costs fluctuate sharply from year to year, according to survey results released by Japan's Pharmaceutical Manufacturers Association

Japan's Clinical Trial Costs Average ¥2 Million; Number Of Trials On The Rise

TOKYO - The number of clinical trials being performed in Japan is trending upward every year, but trial costs fluctuate sharply from year to year, according to survey results released by Japan's Pharmaceutical Manufacturers Association

As Tokyo Regulators Open More To Global Clinical Trial Data, Some Japanese Drug Outfits Move West To Expand

Leaders of the India-based Veeda Clinical Research said that by placing a bridging study leg in a clinical trial program early on time lags that often exist between regulatory agencies in the West and in Asia can be further reduced. That strategy can also expedite a drug's entry into other markets and thus benefit both patients and the pharmaceutical companies behind the new products

Related Content

UsernamePublicRestriction

Register

SC072754

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel